Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du Sells 46,389 Shares of Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 46,389 shares of the firm’s stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $28.09, for a total transaction of $1,303,067.01. Following the completion of the sale, the chief executive officer now owns 479,851 shares in the company, valued at $13,479,014.59. This represents a 8.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ying Du also recently made the following trade(s):

• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $28.57, for a total value of $1,428,500.00.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total value of $97,508.95.
• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $208,449.12.
• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total value of $1,622,000.00.
• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.47, for a total value of $1,723,500.00.

Zai Lab Trading Up 2.2%

NASDAQ:ZLAB opened at $28.75 on Friday. The stock has a 50-day moving average price of $32.20 and a 200 day moving average price of $29.69. The stock has a market capitalization of $3.17 billion, a P/E ratio of -10.38 and a beta of 1.04. Zai Lab Limited has a 12-month low of $16.01 and a 12-month high of $39.77.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.05. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. On average, research analysts predict that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Scotiabank initiated coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research note on Thursday, March 27th. Finally, Bank of America restated a “neutral” rating and set a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Hedge Funds Weigh In On Zai Lab

Several institutional investors have recently bought and sold shares of ZLAB. GF Fund Management CO. LTD. purchased a new stake in Zai Lab in the 4th quarter worth $29,000. Pictet Asset Management Holding SA purchased a new stake in shares of Zai Lab in the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Zai Lab in the first quarter worth about $75,000. Advisors Preferred LLC bought a new position in Zai Lab during the first quarter valued at approximately $110,000. Finally, Barclays PLC grew its holdings in Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company’s stock valued at $97,000 after buying an additional 2,856 shares in the last quarter. 41.65% of the stock is owned by hedge funds and other institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.